About the Program:
Program Overview:
Despite significant advances in the treatment of people with HIV infection, professional practice gaps remain that contribute to continued morbidity and mortality. While clinical trials provide an evidence base regarding which ARV drugs and regimens are most likely to be effective for treating various patients, many HIV clinicians have not integrated them into their clinical practice. To address this problem, we have developed a case-based CME program that explores and analyzes current HIV treatment standards of care, including when to start, what to start in ARV-naive patients, and when to switch ARVs in virologically suppressed patients for the purpose of eliminating or avoiding toxicity, improving long-term patient health, or simplifying a regimen. Participants in this program will gain knowledge and skills that should lead to improved patient care.
Target Audience:
This activity is intended for physicians, physician assistants, advanced practice nurses, general practitioners and other health care professionals involved in the treatment and management of patients who have or are at risk of HIV infection.
Learning Objectives:
Upon completion of the program, participants should be able to:
- Provide timely, effective, and individualized ARV therapy to treatment-naïve patients with HIV infection
- Apply in clinical practice approaches for maintaining long-term viral suppression, including appropriate switching of ARV therapy
- Apply knowledge and skills for selecting the most effective ARV therapy for treatment-experienced patients
- Manage ARV therapy in special populations with HIV infection to address issues associated with special needs and co-morbidities, such as cardiovascular, renal, and bone disease
Release Date: March 26, 2018
Expiration Date: March 26, 2019
Estimated time to complete each Module: 30 minutes
Media: Web
Faculty:
Richard A. Elion, MD
Associate Professor of Clinical Medicine
George Washington University Medical Center
Washington, DC
Wilbert Jordan, MD
Medical Director
Charles Drew Medical Center
Los Angeles, California
Paul Sax, MD
Clinical Director
Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Renslow Sherer, MD
Professor of Medicine
Section of Infectious Diseases and Global Health
University of Chicago
Chicago, Illinois
Joint Accreditation Statement:
 |
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ViralEd, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
| The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. |
Credit Designation:
Module 1 (Treatment-Naïve: Asymptomatic):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 2 (Treatment-Naïve: Special Populations):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 3 (Treatment-Experienced: Virologic Failure):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 4 (Treatment- Experienced: Toxicity Issues and Convenience):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest:
Postgraduate Institute for Medicine (PIM) requires instructors,
planners, managers and other individuals who are in a position to
control the content of this activity to disclose any real or apparent
conflict of interest (COI) they may have as related to the content of
this activity. All identified COI are thoroughly vetted and resolved
according to PIM policy. PIM is committed to providing its learners with
high quality CME activities and related materials that promote
improvements or quality in healthcare and not a specific proprietary
business interest of a commercial interest.
The faculty reported the following financial relationships
or relationships to products or devices they or their spouse/life
partner have with commercial interests related to the content of this
CME activity:
Richard A. Elion, MD:
- Consulting Fees: Gilead, ViiV
- Fees for Non-CME Services: Gilead, Merck, Janssen
|
| Wilbert Jordan, MD:
|
Paul Sax, MD:
- Consulting Fees: AbbVie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV, Janssen, Merck
- Contacted Research: NIH, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV, Merck
- Other (Editorial Boards): Medscape, UpToDate, Open Forum Infectious Diseases
|
Renslow Sherer, MD:
|
The planners and managers reported the following financial relationships
or relationships to products or devices they or their spouse/life
partner have with commercial interests related to the content of this
CME activity:
The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN,
Trace Hutchison, PharmD, Samantha Mattucci, PharmD, CHCP and Jan
Schultz, MSN, RN, CHCP, hereby state that they or their spouse/life
partner do not have any financial relationships or relationships to
products or devices with any commercial interest related to the content
of this activity of any amount during the past 12 months.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this activity. During the period, March 26, 2018 through March 26, 2019, participants must read the learning objectives and faculty disclosures and study the educational activity.
PIM supports Green CME by offering your Request for Credit online. If
you wish to received acknowledgment of completing this activity, please
complete the post-test and evaluation on http://www.cmeuniversity.com/. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 13209. Upon registering and successfully completing the post-test with a
score of 70% or better and the activity evaluation, your certificate
will be made available immediately. Processing credit requests online
will reduce the amount of paper used by nearly 100,000 sheets per year.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. The
planners of this activity do not recommend the use of any agent outside
of the labeled indications.
The opinions expressed in the educational activity are those of the
faculty and do not necessarily represent the views of the planners.
Please refer to the official prescribing information for each product
for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired
information to enhance patient outcomes and their own professional
development. The information presented in this activity is not meant to
serve as a guideline for patient management. Any procedures,
medications, or other courses of diagnosis or treatment discussed or
suggested in this activity should not be used by clinicians without
evaluation of their patient's conditions and possible contraindications
on dangers in use, review of any applicable manufacturer's product
information, and comparison with recommendations of other authorities.
This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs
Jointly provided by the Postgraduate Institute for Medicine and ViralEd, Inc.
|
